Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Lily Guo
 + 689 word(s) 689 2020-12-15 08:05:17

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Guo, L. PMS2 Gene. Encyclopedia. Available online: https://encyclopedia.pub/entry/5779 (accessed on 21 December 2024).
Guo L. PMS2 Gene. Encyclopedia. Available at: https://encyclopedia.pub/entry/5779. Accessed December 21, 2024.
Guo, Lily. "PMS2 Gene" Encyclopedia, https://encyclopedia.pub/entry/5779 (accessed December 21, 2024).
Guo, L. (2020, December 25). PMS2 Gene. In Encyclopedia. https://encyclopedia.pub/entry/5779
Guo, Lily. "PMS2 Gene." Encyclopedia. Web. 25 December, 2020.
PMS2 Gene
Edit
This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/gene/pms2

PMS1 homolog 2, mismatch repair system component

genes

1. Introduction

The PMS2 gene provides instructions for making a protein that plays an essential role in repairing DNA. This protein helps fix errors that are made when DNA is copied (DNA replication) in preparation for cell division. The PMS2 protein joins with another protein called MLH1 (produced from the MLH1 gene) to form a two-protein complex called a dimer. This complex coordinates the activities of other proteins that repair errors made during DNA replication. Repairs are made by removing the section of DNA that contains errors and replacing it with a corrected DNA sequence. The PMS2 gene is a member of a set of genes known as the mismatch repair (MMR) genes.

2. Health Conditions Related to Genetic Changes

2.1. Constitutional mismatch repair deficiency syndrome

More than 55 mutations in the PMS2 gene have been associated with a condition called constitutional mismatch repair deficiency (CMMRD) syndrome. PMS2 gene mutations are the most frequent cause of this condition. Individuals with CMMRD syndrome are at increased risk of developing cancers of the colon (large intestine) and rectum (collectively referred to as colorectal cancer), brain, and blood (leukemia or lymphoma). These cancers usually first occur in childhood, with the vast majority of cancers in CMMRD syndrome diagnosed in people under the age of 18. Many people with CMMRD syndrome also develop changes in skin coloring (pigmentation), similar to those that occur in a condition called neurofibromatosis type 1.

Individuals with CMMRD syndrome inherit two PMS2 gene mutations, one from each parent, while people with Lynch syndrome (described below) have a mutation in one copy of the PMS2 gene.

PMS2 gene mutations result in near or complete loss of PMS2 protein production. A shortage of this protein eliminates mismatch repair activity and prevents the proper repair of DNA replication errors. These errors accumulate as the abnormal cells continue to divide. The errors disrupt other genes involved in important cellular processes, such as controlling cell growth and division (proliferation). If cell growth is uncontrolled, it can lead to childhood cancer in people with CMMRD syndrome.

It is thought that the features of neurofibromatosis type 1 in people with CMMRD syndrome are due to genetic changes in the NF1 gene that result from loss of mismatch repair. These changes are present only in certain cells (somatic mutations), whereas NF1 gene mutations that are present in all cells of the body cause neurofibromatosis type 1.

2.2. Lynch syndrome

Mutations in the PMS2 gene have been reported in about 6 percent of families with Lynch syndrome that have an identified gene mutation. Lynch syndrome increases the risk of many types of cancer, particularly colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the endometrium (lining of the uterus), ovaries, stomach, small intestine, liver, gallbladder ducts, upper urinary tract, and brain. By age 75, the risk of developing one of these cancers is 30 percent for women and 25 percent for men with a PMS2 gene mutation. These mutations lead to a form of Lynch syndrome with a lower risk of cancer development compared to other causes of this condition. Additionally, in people with a PMS2 gene mutation, cancer tends to occur at a later age compared to others with Lynch syndrome. The reason for this lower cancer risk is unclear.

PMS2 gene mutations involved in this condition lead to the production of an abnormally short or inactive PMS2 protein from one copy of the gene. The altered protein cannot efficiently repair errors made during DNA replication. The errors accumulate as the cells continue to divide, increasing the risk of tumor formation in the colon or another part of the body.

Because there is some functional PMS2 protein produced from the normal copy of the gene, mismatch repair activity in Lynch syndrome is reduced but not absent, as it is in CMMRD syndrome (described above). This difference in DNA repair activity levels likely explains why cancers in Lynch syndrome generally develop in adulthood while those in CMMRD syndrome often affect children.

2.3. More About This Health Condition

Alopecia areata

Ovarian cancer

3. Other Names for This Gene

  • PMS2 postmeiotic segregation increased 2 (S. cerevisiae)
  • PMS2_HUMAN
  • postmeiotic segregation increased (S. cerevisiae) 2

References

  1. Bandipalliam P. Syndrome of early onset colon cancers, hematologicmalignancies & features of neurofibromatosis in HNPCC families with homozygousmismatch repair gene mutations. Fam Cancer. 2005;4(4):323-33. Review.
  2. Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP,Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, BalaguerF, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen CappelWH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A,Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H,Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, Knebel Doeberitz MV, LoefflerM, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, PylvänäinenK, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, LeMarchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C,Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M,Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, PineroTA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin JP, Nielsen M, Møller P. Cancer risks by gene, age, and gender in 6350 carriersof pathogenic mismatch repair variants: findings from the Prospective LynchSyndrome Database. Genet Med. 2020 Jan;22(1):15-25. doi:10.1038/s41436-019-0596-9.Sep;22(9):1569.
  3. Gill S, Lindor NM, Burgart LJ, Smalley R, Leontovich O, French AJ, GoldbergRM, Sargent DJ, Jass JR, Hopper JL, Jenkins MA, Young J, Barker MA, Walsh MD,Ruszkiewicz AR, Thibodeau SN. Isolated loss of PMS2 expression in colorectalcancers: frequency, patient age, and familial aggregation. Clin Cancer Res. 2005 Sep 15;11(18):6466-71.
  4. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, ClendenningM, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, dela Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S,Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, TerdimanJP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016 Jan;18(1):13-9. doi: 10.1038/gim.2015.27.
  5. Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau H, van Puijenbroek M, Tops C, van Os T, Wagner A, Ausems MG, Gomez E, Breuning MH, Bröcker-VriendsAH, Vasen HF, Wijnen JT. Heterozygous mutations in PMS2 cause hereditarynonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology. 2006Feb;130(2):312-22.
  6. Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [updated 2018 Apr 12]. In:Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A,editors. GeneReviews® [Internet]. Seattle (WA): University of Washington,Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/
  7. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003Mar 6;348(10):919-32. Review.
  8. Peltomäki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227-32. Review.
  9. Santucci-Darmanin S, Paquis-Flucklinger V. [Homologs of MutS and MutL duringmammalian meiosis]. Med Sci (Paris). 2003 Jan;19(1):85-91. Review. French.
  10. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM,Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A. The clinical phenotype ofLynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008Aug;135(2):419-28. doi: 10.1053/j.gastro.2008.04.026.
  11. Tamura K, Kaneda M, Futagawa M, Takeshita M, Kim S, Nakama M, Kawashita N,Tatsumi-Miyajima J. Correction to: Genetic and genomic basis of the mismatchrepair system involved in Lynch syndrome. Int J Clin Oncol. 2019 Sep;24(9):1012. doi: 10.1007/s10147-019-01515-w.
  12. Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, de la Chapelle A, Capella G, Clendenning M, Engel C, Gallinger S, Gomez Garcia E,Figueiredo JC, Haile R, Hampel HL, Hopper JL, Hoogerbrugge N, von KnebelDoeberitz M, Le Marchand L, Letteboer TGW, Jenkins MA, Lindblom A, Lindor NM,Mensenkamp AR, Møller P, Newcomb PA, van Os TAM, Pearlman R, Pineda M, Rahner N, Redeker EJW, Olderode-Berends MJW, Rosty C, Schackert HK, Scott R, Senter L,Spruijt L, Steinke-Lange V, Suerink M, Thibodeau S, Vos YJ, Wagner A, Winship I, Hes FJ, Vasen HFA, Wijnen JT, Nielsen M, Win AK. Cancer Risks for PMS2-AssociatedLynch Syndrome. J Clin Oncol. 2018 Oct 10;36(29):2961-2968. doi:10.1200/JCO.2018.78.4777.20;37(9):761.
  13. Truninger K, Menigatti M, Luz J, Russell A, Haider R, Gebbers JO, Bannwart F, Yurtsever H, Neuweiler J, Riehle HM, Cattaruzza MS, Heinimann K, Schär P, JiricnyJ, Marra G. Immunohistochemical analysis reveals high frequency of PMS2 defectsin colorectal cancer. Gastroenterology. 2005 May;128(5):1160-71.
  14. Vaughn CP, Baker CL, Samowitz WS, Swensen JJ. The frequency of previouslyundetectable deletions involving 3' Exons of the PMS2 gene. Genes ChromosomesCancer. 2013 Jan;52(1):107-12. doi: 10.1002/gcc.22011.
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Genetics & Heredity
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Lily Guo
View Times: 528
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 25 Dec 2020
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback